cc-5013
Duffy Blood Group, Chemokine Receptor Gene Mutation
Andrew Hantel, MDPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 81/ 100
Competitive context
11 Active assets in the Duffy Blood Group, Chemokine Receptor Gene Mutation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DEXAMETHASONE Andrew Hantel, MD | Phase 1 | CC |
CIS-DIAMMINEDICHLOROPLATINUM II Andrew Hantel, MD | Phase 1 | CC |
Epirubicin Andrew Hantel, MD | Phase 1 | CC |
DARATUMUMAB Andrew Hantel, MD | Phase 1 | CC |
Carboplatin Andrew Hantel, MD | Phase 1 | CC |
View all 11 →
Same molecule, other indications
cc-5013 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →